Article Text


Recommendations for the management of autoinflammatory diseases
  1. Nienke M ter Haar1,2,
  2. Marlen Oswald3,
  3. Jerold Jeyaratnam4,
  4. Jordi Anton5,
  5. Karyl S Barron6,
  6. Paul A Brogan7,
  7. Luca Cantarini8,
  8. Caroline Galeotti9,
  9. Gilles Grateau10,
  10. Veronique Hentgen11,
  11. Michael Hofer12,
  12. Tilmann Kallinich13,
  13. Isabelle Kone-Paut14,
  14. Helen J Lachmann15,
  15. Huri Ozdogan16,
  16. Seza Ozen17,
  17. Ricardo Russo18,
  18. Anna Simon19,
  19. Yosef Uziel20,
  20. Carine Wouters21,
  21. Brian M Feldman22,
  22. Sebastiaan J Vastert2,
  23. Nico M Wulffraat2,
  24. Susanne M Benseler23,
  25. Joost Frenkel4,
  26. Marco Gattorno24,
  27. Jasmin B Kuemmerle-Deschner3
  1. 1Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
  2. 2Department of Paediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  3. 3Division of Paediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany
  4. 4Department of Paediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
  5. 5Paediatric Rheumatology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
  6. 6Division of Intramural Research, National Institute of Health, Bethesda, USA
  7. 7Department of Rheumatology, UCL Institute of Child Health, London, UK
  8. 8Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy
  9. 9Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, Paris, France
  10. 10Department of Internal Medicine, APHP, Hôpital Tenon, University Pierre-et-Marie-Curie, Paris, France
  11. 11French Reference Centre for Auto-Inflammatory Diseases in Children, Centre Hospitalier de Versailles, Le Chesnay Cedex, France
  12. 12Department of Paediatrics, University of Lausanne, Lausanne, Switzerland
  13. 13Department of Paediatric Pneumology and Immunology, Charité University Medicine, Berlin, Germany
  14. 14Department of Paediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France
  15. 15National Amyloidosis Centre, University College London Medical School, London, UK
  16. 16Division of Rheumatology, Cerrahpasa Ic Hastaliklari Klinigi, University Istanbul, Istanbul, Turkey
  17. 17Department of Paediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
  18. 18Service of Immunology and Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina,
  19. 19Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
  20. 20Department of Paediatrics, Meir Medical Center, Tel-Aviv University, Tel-Aviv, Israel
  21. 21Department of Microbiology and Immunology, University Hospital Leuven, Leuven, Belgium
  22. 22Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada
  23. 23Department of Paediatrics, Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, Canada
  24. 24Division of Paediatrics II, G. Gaslini Institute, Genoa, Italy
  1. Correspondence to Nienke ter Haar, Department of Paediatric Immunology, and Laboratory for Translational Immunology, University Medical Center Utrecht, Lundlaan 6, Utrecht 3584 EA, The Netherlands; n.m.terhaar-2{at}


Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and (paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with ≥80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD.

  • Fever Syndromes
  • Treatment
  • Multidisciplinary team-care

Statistics from


Autoinflammatory diseases (AID) are rare disorders that affect multiple organ systems and lead to significant morbidity and mortality. Due to the low patient numbers, evidence-based guidelines for treatment are lacking and management is mostly based on physician's experience. As new effective therapeutic options are now available, early diagnosis and treatment might prevent significant organ damage. Reliable recommendations can thus help paediatricians and (paediatric) rheumatologist in the care of patients with these rare diseases.

In 2012, a European initiative called SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.1 One of the aims of SHARE was to provide evidence-based recommendations for the management of paediatric rheumatic diseases.

In this paper, we propose recommendations for the management of three of the main monogenic AID:

  1. Cryopyrin-associated periodic syndromes (CAPS), caused by gain-of-function mutations in NLRP3, is a spectrum of diseases that includes the relatively mild familial cold autoinflammatory syndrome (FCAS), the intermediate Muckle-Wells syndrome (MWS) and the severe neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurological, cutaneous and articular syndrome (CINCA) and their overlaps (FCAS-MWS and MWS-CINCA).2 CAPS is characterised by fever, urticarial rash, conjunctivitis and articular involvement (typically triggered by cold exposure in FCAS); more severely affected patients with CAPS may also have hearing loss, visual loss, chronic meningitis and amyloidosis.3 ,4

  2. Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal dominant inherited disease. Mutations in TNFRSF1A lead to recurrent fever episodes lasting, on average, 10 days, accompanied by varying symptoms including arthralgia, myalgia and abdominal pain.5

  3. Mevalonate kinase deficiency (MKD), including hyperimmunoglobulin D syndrome and the more severe mevalonic aciduria (MA), is an autosomal recessive metabolic inflammatory disease caused by mutations in MVK, affecting the mevalonate pathway.6 Fever episodes usually last 3–7 days, with lymphadenopathy, abdominal symptoms, arthralgia and a maculopapular skin rash.7 In addition to the systemic inflammation, patients with MA have a severe metabolic phenotype, including growth retardation, ataxia and cognitive impairment.8


An international panel consisting of 22 experts in paediatric or adult rheumatology, internal medicine or nephrology was established to develop evidence-based recommendations for the management and treatment of CAPS, TRAPS and MKD using the European League Against Rheumatism (EULAR) standard operating procedures for developing best practice.9 ,10 Eleven of 22 experts were part of the SHARE consortium; 11 additional experts were asked to join the panel based upon their clinical and research expertise in AID.

Systematic literature search

A systematic literature search was performed in Pubmed, Embase and Cochrane databases on 20 June 2013. All synonyms of CAPS, TRAPS and MKD were searched in MeSH/Emtree terms, title and abstract. Further, we searched on ‘autoinflammatory diseases’ and synonyms, and manually checked references of relevant original studies and reviews for missing articles. For more details on the literature search, refer to online supplementary figures S1, S2 and S3. Fellows (NMtH, MO, JJ) and experts (JBK-D, SMB, MG, JF) selected the relevant papers for validity assessment. Complete reference lists of full-text screened papers can be found in the online supplement.

Validity assessment

A panel of experts (two per paper) independently graded the selected papers on methodological quality and extracted data using predefined scoring forms for diagnostic studies,11 therapeutic studies12 and studies describing prognosis and complications.13 Discrepancies were resolved by discussion between the two experts, or by the opinion of a third expert in select instances. Adapted classification tables for diagnostic,14 therapeutic9 and epidemiological studies15 were used to determine the level of evidence and the strength of each recommendation.

Recommendation development

Recommendations were derived from the available literature and distributed to all experts in an online survey. The drafted recommendations were revised according to comments from the survey and proposed at a face-to-face consensus meeting, where they were discussed by the use of Nominal Group Technique,16 supervised by an expert (BMF) in consensus building. Recommendations were accepted when ≥80% of the experts agreed.


Literature review

The literature search yielded 1698 unique papers for CAPS, 523 for TRAPS and 618 for MKD. After title/abstract and subsequently full-text screening, 25 CAPS papers, 22 TRAPS papers and 28 MKD papers were assessed for validity and level of evidence, of which 17/25, 17/22 and 17/28 respectively were considered valid and used for recommendation synthesis. For more details, refer to online supplementary figures S1, S2 and S3.


In the following section, we describe each recommendation with the corresponding supporting literature and discuss issues regarding practical implementation. Tables 13 summarise the recommendations, their levels of evidence, the recommendation strength and percentage of expert agreement for each. Four additional recommendations, specifically on diagnosis of TRAPS and MKD can be found in online supplementary table S1. Recommendations that did not meet ≥80% agreement are listed in online supplementary table S2.

Table 1

Overarching principles for CAPS, TRAPS and MKD

Table 2

Recommendations for the treatment of CAPS, TRAPS and MKD

Table 3

Recommendations for monitoring of CAPS, TRAPS and MKD

Overarching principles

AID affect multiple organ systems with potentially severe complications;4 ,5 ,7 ,8 ,17–26 hence, management of these patients is complex and warrants a multidisciplinary approach: this could involve physiotherapists, paediatricians, rheumatologists and other specialists when specific organs are involved, for example, ENT specialists, ophthalmologists or nephrologists. Furthermore, access to genetic expertise is important because interpretation of genetic results and genetic counselling for family members may be challenging.27 For MA, expertise in metabolic diseases is also required.

Given the lifelong duration of AID and impact on patients’ and families’ life, care should be patient-centred and family-centred, as is the case for most (chronic) diseases.28 Patients with CAPS, TRAPS and MKD have an impaired quality of life compared with healthy controls, in both physical and psychosocial domains, and could encounter limitations in education and daily activities.7 ,25 ,29 It is therefore important to offer psychosocial support as appropriate.

Treatment goals should include control of the disease activity and prevention of organ damage, since effective therapy might prevent or stabilise organ damage.21 ,30 ,31 Effective treatment can also improve participation in daily activities and quality of life; this is thus an important additional goal of therapy.31–33


Early diagnosis is crucial to enable treatment initiation before damage occurs. Although diagnostic delay has decreased in the last decades, the median time between onset of symptoms and diagnosis is still 1–2 years.34 The diagnostic score for molecular analysis of patients with recurrent fever35 and the recently published clinical classification criteria for the diagnosis of monogenic AID36 can facilitate the diagnostic process and decrease this delay. We refer to these papers for more details. For CAPS, diagnostic criteria are currently being developed.

Interpretation of genetic tests can also be challenging, especially with low-penetrance TNFRSF1A mutations or NLRP3 mutation-negative CAPS patients. Recently published guidelines for genetic diagnosis of AID can guide physicians and geneticists.27 We support the use of these guidelines in the diagnostic process. Specific recommendations on diagnosis, for example, the use of serum immunoglobulin D and urinary mevalonic acid excretion in the diagnostic process of MKD, can be found in supplementary table S1.


Cryopyrin-associated periodic syndromes

Three interleukin (IL)-1 blocking agents are currently used for CAPS. For a summary of the evidence and the authorisation of the European Medicines Agency (EMA) and Food and Drug Administration (FDA), refer to table 4 and the websites of both organisations.37 ,38

Table 4

Summary of evidence and regulatory authorisations for IL-1 blockade and TNF-blockade

Anakinra was effective in observational studies of patients with CINCA/NOMID (aged 9 months–42 years),31 ,39 ,40 MWS (3–75 years)40–42 and adult patients with FCAS.40 ,43 Starting dose of anakinra varied between 0.5 and 2 mg/kg/day (children) or 100 mg (adults) subcutaneously, but some patients, especially young children, required dose escalation up to 5 or 8 mg/kg/day to achieve sustained remission.31 ,42 A study on pharmacokinetics of anakinra supports this finding: in order to reach the same effective steady-state concentration, young children need higher doses of anakinra.44

Canakinumab was effective in two randomised controlled trials (RCTs) of patients with CAPS (MWS and CINCA/MWS-overlap, aged 9–74 years),32 ,45 and in four observational studies of all disease phenotypes and age categories.40 ,42 ,46 ,47 Canakinumab was administered subcutaneously at a dose of 2 mg/kg (children) or 150 mg (adults) once per 8 weeks, but one study mentions that 24% of 166 patients required dose escalation up to 8 mg/kg or 600 mg; this was especially the case for paediatric patients or patients with more severe phenotypes.47

The efficacy of rilonacept (2.2 mg/kg or 160 mg weekly) was demonstrated in one RCT including adult patients with MWS and FCAS48 and two observational studies including patients with MWS and FCAS aged 12–80 years.40 ,49

In CAPS, there is no evidence for the efficacy of disease-modifying antirheumatic drugs or biological therapy other than IL-1 blockade.50 Some patients benefit from non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, mostly as on-demand symptom relief next to IL-1 blocking agents.39 ,50 Because of the lack of valid literature on efficacy and prevention of organ damage if used solely, we do not recommend the use of NSAIDs and corticosteroids without IL-1 inhibition.

Organ damage such as hearing loss, neurological damage and joint deformity causes considerable morbidity in patients with CAPS and can partly be stabilised or improved with IL-1 inhibition.21 ,30 ,31 ,51 Therefore, it is important to start IL-1 inhibition early, before severe damage occurs. When patients develop irreversible damage, they may need adjunctive therapy such as physiotherapy, orthotic devices and hearing aids.

TNF receptor-associated periodic syndrome

Evidence for therapy of patients with TRAPS relies on retrospective cohorts or small prospective studies at best. In one retrospective cohort, NSAIDs provided symptom relief in approximately 75% of patients with TRAPS, but were rarely completely effective in terminating inflammatory episodes.50 Efficacy of corticosteroids has only been assessed in retrospective studies, in which most patients reported a beneficial effect.23 ,50 ,52–54 Unfortunately, this initial favourable response often declines with time.53

A summary of the evidence and authorisation details for IL-1 blocking and TNF-blocking agents is provided in table 4. Etanercept efficacy was assessed in two small prospective studies; these demonstrated significant improvement in symptoms and inflammatory parameters in most patients but also highlighted declining efficacy over time. This latter finding was the reason for discontinuing etanercept in 11/13 patients in one study.55–57 Loss of etanercept efficacy was also reported in larger retrospective studies describing transient responses, and a complete remission rate of less than one-third of patients.50 ,58 Anakinra was effective as on-demand as well as maintenance therapy in a small prospective study.59 Retrospective studies confirm this finding; a complete response was reported in two-thirds of the patients.50 ,58 However, anakinra-failure was also observed.50 ,60

Because long-term disease activity can cause AA amyloidosis5 and long-term use of corticosteroids can induce significant side-effects,61–63 we recommend maintenance therapy with IL-1 blockade or etanercept in patients with frequent attacks and/or ongoing (subclinical) inflammation. In retrospective studies, IL-1 blockade seems to be superior to etanercept.50 However, as prospective randomised trials comparing efficacy between these drugs are lacking, insufficient evidence is available to clearly recommend one specific agent as first-line.

Evidence in TRAPS for switching from one biological agent to another is restricted to one study that showed efficacy of anakinra after patients experienced loss of efficacy to etanercept.55 Studies in other diseases also suggest that switching could be beneficial and should be considered when the initial treatment choice is ineffective or intolerable.42 ,64 For IL-1 blockade, dose adjustments might be necessary to achieve complete response, as has been shown in patients with CAPS.31 ,42 ,44 ,47

The use of adalimumab and infliximab induces variable results in case reports, including failure and even worsening of TRAPS symptoms; these drugs are thus not recommended.50 ,56 ,57

Mevalonate kinase deficiency

Treatment efficacy in MKD is mostly described in retrospective cohorts. Most patients benefited from the use of NSAIDs, mainly given during inflammatory attacks.7 ,8 ,50 However, NSAIDs are not effective for terminating inflammatory attacks. Similarly, the efficacy of glucocorticoids has only been assessed retrospectively, and most patients derive some therapeutic benefit.7 ,8 ,50 Colchicine and statins are ineffective; moreover, statins induced a severe attack in a patient with MA.7 ,8 ,26 ,50

A small prospective study showed that anakinra on demand significantly reduced all features of the fever episode compared with attacks not treated with anakinra.65 When patients have frequent attacks and/or subclinical inflammation between attacks, maintenance therapy with IL-1 blockade or etanercept is recommended. Continuous IL-1 blockade with anakinra or canakinumab, or TNF-blockade with etanercept or adalimumab, was beneficial in approximately two-thirds of reported patients.7 ,26 ,50 ,66 Because head-to-head comparisons are lacking, it is not possible to recommend any one of these agents as first-line biological therapy. Table 4 summarises the evidence relating to IL-1 and TNF-blocking agents in MKD. Although there is currently no evidence to support switching biological agents in MKD when initial treatment fails, based on the success of this approach in other diseases,42 ,64 this should be considered. Again, for IL-1 blockade, dose adjustments might be tried first, as the initial dose might be insufficient.

In selected cases with severe refractory disease and poor quality of life, allogeneic haematopoietic stem cell transplantation (HSCT) could be a valuable option. Four cases of successful allogeneic HSCT have been reported: all experienced a remission of systemic inflammation and an improvement of neurological symptoms.67–69 Nonetheless, because of the inherent risks associated with HSCT, this should only be considered in severely affected patients resistant to (or intolerant of) all the other aforementioned therapeutic agents.



Since disease-related and treatment-related morbidity is common, and dose adjustment of IL-1 blocking agents to achieve complete remission may be required, regular monitoring is crucial.39 ,47 Disease severity varies widely among patients, and thus we recommend that the specific monitoring frequency should be tailored to suit individual patient requirements.

The use of a validated disease activity score is crucial for standardised monitoring of patients with AID. The Autoinflammatory Diseases Activity Index (AIDAI) is the only validated disease activity index for TRAPS and MKD, and one of the validated scores for CAPS.70 ,71 Another validated disease activity score for patients with CAPS is the MWS Disease Activity Score (MWS-DAS).72 To increase standardised outcome measurements and thus improve comparisons between studies, we recommend that a validated score should be used in clinical studies of patients with AID: the AIDAI for TRAPS and MKD, and either the AIDAI or MWS-DAS for CAPS.

During monitoring, patients may experience inflammatory episodes that are atypical of their disease; it is important to be aware of other causes of these atypical episodes. Infections are common, especially in children, and might be more common or more dangerous in patients with AID due to their disease and/or immunosuppressive medication.26 ,31 ,39 ,41–43 ,45 ,47 ,49 ,73 When initiating therapy with biological agents, consideration should be made to give live-attenuated and non-live vaccines as appropriate. According to EULAR recommendations for vaccination in patients with rheumatic diseases, physicians should withhold live-attenuated vaccines when a patient is treated with biological agents.74 ,75 Some studies suggest that live-attenuated booster vaccination against measles-mumps-rubella and yellow fever can be safely used in patients using TNF-blocking agents.76–78 Evidence on safety of vaccinations during IL-1 blocking agents is limited to one randomised study of healthy subjects79 and a note that 25 patients with CAPS on canakinumab received vaccinations without abnormal immune responses or pathogen-related infections.47 However, data on live-attenuated vaccines are still scarce; hence we concluded that there are currently insufficient safety data to recommend live vaccines during therapy with biological agents, especially during IL-1 blockade.

Cryopyrin-associated periodic syndromes

Experts created a list of items that should be included in the monitoring of all patients with CAPS (table 3), based on all relevant symptoms and complications described in patients with CAPS as well as the impact of disease on daily life.17 ,18 ,20 ,21 ,30 ,32 ,72 ,80–83 For the more severe CAPS phenotypes, additional tests such as imaging of bone and brain, including inner ear should be considered, as well as cognitive testing and lumbar puncture to assess chronic meningitis. Because bone overgrowth mainly involves the lower limbs, we recommend performing imaging (including skeletal X-ray and MRI) of the femurs, patellae and tibiae.

TNF receptor-associated periodic syndrome

Most TRAPS symptoms can be assessed by history taking and physical examination.5 ,22–25 Amyloidosis is described in about 10% of the patients with TRAPS and occurs more often in patients with long disease duration.5 ,22 ,23 ,84 Hence, inflammatory parameters and proteinuria should be checked regularly.5 ,22 ,23 A list of particularly relevant items to check when monitoring a patient with TRAPS can be found in table 3.

Interpretation of the low-penetrance variants R92Q and P46L can be difficult, as 1%–2% of asymptomatic controls also harbour these variants.22 ,84 Patients with R92Q or P46L variants who experience symptoms compatible with TRAPS have a similar phenotype as patients with other TNFRSF1A mutations, although sometimes with shorter and/or more frequent fever episodes.5 ,23 ,25 These patients are also more likely to have a milder disease course (resolution or decrease in fever episodes) and a decreased risk of developing AA amyloidosis compared with patients with structural TNFRSF1A mutations.5 ,22 ,23 ,25

Mevalonate kinase deficiency

Most of the mild MKD symptoms can be assessed by history taking and physical examination and routine laboratory measures such as full blood count, C-reactive protein (CRP) and serum amyloid A (SAA) to assess systemic inflammation.7 ,26 Urine analysis should be performed for renal complications such as AA amyloidosis, glomerulonephritis and renal angiomyolipoma7 ,26 as well as ophthalmological examination for retinitis pigmentosa and cataracts.26 ,85

Patients with more severe MKD phenotypes have neurological complications such as ataxia, hypotonia and psychomotor retardation; thus cognitive testing and full neurological examination should be considered.8 ,26 Since hepatitis and myopathy are also reported in these patients, testing muscle and liver enzymes may be relevant. A list of items particularly relevant for monitoring MKD is provided in table 3.

In addition to an increased infection risk, physicians should also be aware of a higher risk of macrophage activation syndrome (MAS) in patients with MKD, especially in the assessment of atypical fever episodes. MAS is a life-threatening complication of some rheumatic diseases (eg, systemic juvenile idiopathic arthritis), characterised by high fever, pancytopenia and liver damage.86 In one cohort of patients with MKD, the frequency of MAS was surprisingly high (6/50, 12%).26


The SHARE taskforce formulated a total of 42 recommendations for the management of patients with the autoinflammatory diseases CAPS, TRAPS and MKD, based on a systematic literature review and consensus procedure.

Biological therapies have dramatically improved the outcome of patients with AID; this is especially true for patients with CAPS on IL-1 blockade. However, evidence supporting the use of biologicals is still very limited in TRAPS and MKD. Prospective studies and head-to-head comparisons are needed to draw solid conclusions on the efficacy of biologicals and to enable EMA/FDA approval. At the time of writing, prospective clinical trials are ongoing: two Phase 2 studies on canakinumab for MKD (NCT01303380) and TRAPS (NCT01242813) and a Phase 3 study on canakinumab for hereditary periodic fevers (NCT02059291).87 Regarding the use of IL-1 blockade in very young children with CAPS, the current regulatory approvals by FDA and EMA are provided in table 4. It is recognised, however, that some young patients with severe CAPS may require treatment earlier in life than currently recommended by the authorities. Studies on the safety of canakinumab in the very young are soon-to-be published.

Close monitoring of patients’ symptoms, damage and well-being is an important requirement for ‘treat to target’ strategies. Structured long-term follow-up studies of patients with AID are warranted to clarify complication risks. Given the rarity of these diseases, international collaboration is crucial to recruit sufficient patient numbers. Validated scores for disease activity and damage are essential in order to perform a structured assessment of outcome, especially to determine long-term therapeutic efficacy and therapy-associated morbidity. Disease activity scores have now been developed, however, disease damage scores are still lacking.

A significant limitation of these recommendations is the lack of high-quality evidence. Other than the use of IL-1 blockade in CAPS, most topics are not thoroughly studied. Thus, most of our recommendations have a strength C or D and depend mainly on expert opinion. Therefore, further research on complications, monitoring and the use of biological agents in TRAPS and MKD is necessary to enable better evidence-based recommendations. To conclude, based on the best available evidence and expert opinion, this SHARE initiative provides recommendations on diagnosis, treatment and monitoring of CAPS, TRAPS and MKD, aiming to optimise the management of these rare patients.


This SHARE initiative has been endorsed by the executive committee of the Paediatric Rheumatology European Society (PReS) and the International Society of Systemic Auto-Inflammatory Diseases (ISSAID).


View Abstract

Review history and Supplementary material

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Handling editor Tore K Kvien

  • JF, MG and JBK-D contributed equally.

  • Contributors NMW and SJV designed the SHARE initiative. NMtH, MO and JJ performed the systematic literature review, supervised by JF, JBK-D, SMB and MG. Validity assessment of selected papers was done by MH, IK-P, LC, MG and JBK-D (CAPS), MG, HJL, PAB, GG (TRAPS) and JF, AS, JA, CG (MKD). Recommendations were formulated by NMH, MO, JF, JBK-D, SMB and MG. The expert committee consisted of JA, KSB, PAB, LC, CG, GG, VH, MH, TK, IK-P, HJL, HO, SO, RR, AS, YU, CW, SJV, JF, MG and JBK-D; they completed the online surveys and/or participated in the subsequent consensus meeting. BMF assisted in the preparation of the live consensus meeting and led the consensus procedure using nominal group technique. NMtH wrote the manuscript, with contribution and approval of all co-authors.

  • Funding This project is supported by a grant from European Agency for Health and Consumers (EAHC), grant number 2011 1202.

  • Competing interests JA: Grant/Research Support from Abbvie, Novartis, Pfizer, Consultant for Novartis, Speaker Bureau of Abbvie, Novartis, Pfizer, Roche, SOBI; PAB: Grant/Research Support from Novartis, Roche, and SOBI, Consultant for Roche and SOBI; LC: Grant/Research Support from Novartis, SOBI, Consultant for Novartis, SOBI; CG: Grant/Research Support from Novartis; GG: Consultant for Novartis; VH: Consultant for Novartis; MH: Consultant for Novartis; TK: Grant/Research Support from Novartis, Speaker Bureau of Novartis, SOBI; IK-P: Grant/Research Support from Chugai, Novartis, SOBI, Consultant for Abbvie, Chugai, Novartis, Pfizer, SOBI, Speaker Bureau of Novartis, Pfizer; HJL: Research Support and speaker Bureau from Novartis; SO: Consultant for Novartis, Speaker Bureau of SOBI; AS: Consultant for Novartis, Xoma and SOBI; YU: Grant/Research Support from Novartis, Consultant for Novartis, Speaker Bureau of Abbvie, Neopharm, Novartis, Roche; BMF: Consultant for Novartis, Pfizer, BMS; SJV: Consultant for Novartis; NMW: Grant/Research Support from EAHC, Abbvie, GSK, Roche, Consultant for Genzyme, Novartis, Pfizer, Roche; JF: Grant/Research Support from Takeda, Consultant for Novartis, Speaker Bureau of SOBI; MG: Grant/Research Support and speaker Bureau from Novartis and SOBI; JBK-D: Grant/Research Support from Novartis, Speaker Bureau of SOBI.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.